Table 1.
Clinical characteristics of the study population (n=42)
| Variables | Number (%) |
|---|---|
| Gender | |
| Male | 24 (57.1) |
| Female | 18 (42.9) |
| PS | |
| 0–1 | 25 (59.5) |
| 2 | 17 (40.5) |
| Age, years | |
| Median (range) | 56.5 (42–75) |
| >60 | 10 (23.8) |
| ≤60 | 32 (76.2) |
| Smoking history | |
| Yes | 17 (40.5) |
| No | 25 (59.5) |
| Histology | |
| Adenocarcinoma | 30 (71.4) |
| Squamous cell carcinoma | 12 (28.6) |
| EGFR mutation | |
| Yes | 7 (16.7) |
| No | 11 (26.2) |
| Unknown | 24 (57.1) |
| Line of apatinib therapy | |
| Third line | 19 (45.2) |
| Further line | 23 (54.8) |
| Targeted treatment in prior therapy | |
| Yes | 29 (69.0) |
| No | 13 (31.0) |
Abbreviation: PS, performance status.